AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

029 Group SE

Delisting Announcement Sep 4, 2002

4544_rns_2002-09-04_74355431-718f-4b02-880d-2c50fafad941.html

Delisting Announcement

Open in Viewer

Opens in native device viewer

News Details

Ad-hoc | 4 September 2002 08:00

Rhein Biotech N.V. english

Rhein Biotech seeks transfer to the Frankfurt Geregelter Markt Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Rhein Biotech announced today that its managing and supervisory boards have decided to seek a transfer of its listing on the Neuer Markt to the Geregelter Markt Frankfurt. This decision to change segment has been prompted by the successful takeover of Rhein Biotech by Berna Biotech AG on 1 August 2002. Berna Biotech (Swiss Exchange: BBIN) now holds 92.2 percent of Rhein Biotech’s share capital and voting rights. The current low free-float of under 8 percent no longer stands in relation to the relatively high costs associated with a listing on the Neuer Markt. The official application will be submitted to the Deutsche Börse in writing today. The last trading day at the Neuer Markt is expected to be Friday the 20th of September. Rhein Biotech will furthermore evaluate the modalities and consequences of a future de-listing from the Frankfurt stock exchange end of ad-hoc-announcement (c)DGAP 04.09.2002 Issuer’s information/explanatory remarks concerning this ad-hoc-announcement: Berna Biotech AG (Swiss Exchange: BBIN) has acquired 92.2 percent of the Rhein Biotech share capital by means of a friendly takeover. Rhein Biotech is now a full member of the Berna Biotech Group. The integration of the two companies will create a leading player for innovation in vaccines. An update on the progress of the integration will be provided by Berna Biotech in September. For further information please contact: Company Contact: Marcel Jacobs Communication Manager Rhein Biotech N.V. T: +31 (0)43 / 35 67 894 F: +31 (0)43 / 35 67 899 E: [email protected] Media Contact: Carsten Heinrichs IR-Consultant vom Hoff Kommunikation GmbH T: +49 (0)211 / 515 805 12 F: +49 (0)211 / 515 805 55 E: [email protected] ——————————————————————————– WKN: 919544; ISIN: NL0000230324; Index: NEMAX 50 Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, München, Stuttgart, Hannover 040800 Sep 02

Talk to a Data Expert

Have a question? We'll get back to you promptly.